Stacy D Sanford1,2, Jennifer L Beaumont3, Mallory A Snyder3, Jennifer Reichek3,4, John M Salsman5. 1. Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. ssanfor1@nm.org. 2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 675 N. St. Clair Street Suite 21-100, Chicago, IL, 60611, USA. ssanfor1@nm.org. 3. Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA. 4. Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 60611, USA. 5. Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Abstract
PURPOSE: Minimal clinical trial participation among adolescents and young adults (AYAs) with cancer limits scientific progress and ultimately their clinical care and outcomes. These analyses examine the current state of AYA clinical research participation at a Midwestern comprehensive cancer center and affiliated pediatric hospital to advise program development and increase availability of trials and AYA participation. Enrollment is examined across all diagnoses, the entire AYA age spectrum (15-39), and both cancer therapeutic and supportive care protocols. METHODS: his study was a retrospective review of electronic medical records via existing databases and registries for all AYAs. Data were collected for AYAs seen by an oncologist at the adult outpatient cancer center or at the pediatric hospital between the years 2010 and 2014. Descriptive statistics and logistic regression analyses were conducted to characterize this sample. RESULTS: In the pediatric setting, 42.3% of AYAs were enrolled in a study compared to 11.2% in the adult setting. Regression analyses in the pediatric setting revealed that AYAs with private insurance or Caucasian race were more likely to participate. Within the adult setting, ethnicity, race, insurance, and diagnosis were associated with study participation; 54.8% of study enrollments were for cancer therapeutic and 43.4% for supportive care studies. CONCLUSIONS: These results are comparable to previously published data and support the need for new local and national AYA initiatives to increase the availability of and enrollment in therapeutic clinical trials. The same is true for supportive care studies which play a crucial role in improving quality of life.
PURPOSE: Minimal clinical trial participation among adolescents and young adults (AYAs) with cancer limits scientific progress and ultimately their clinical care and outcomes. These analyses examine the current state of AYA clinical research participation at a Midwestern comprehensive cancer center and affiliated pediatric hospital to advise program development and increase availability of trials and AYA participation. Enrollment is examined across all diagnoses, the entire AYA age spectrum (15-39), and both cancer therapeutic and supportive care protocols. METHODS: his study was a retrospective review of electronic medical records via existing databases and registries for all AYAs. Data were collected for AYAs seen by an oncologist at the adult outpatientcancer center or at the pediatric hospital between the years 2010 and 2014. Descriptive statistics and logistic regression analyses were conducted to characterize this sample. RESULTS: In the pediatric setting, 42.3% of AYAs were enrolled in a study compared to 11.2% in the adult setting. Regression analyses in the pediatric setting revealed that AYAs with private insurance or Caucasian race were more likely to participate. Within the adult setting, ethnicity, race, insurance, and diagnosis were associated with study participation; 54.8% of study enrollments were for cancer therapeutic and 43.4% for supportive care studies. CONCLUSIONS: These results are comparable to previously published data and support the need for new local and national AYA initiatives to increase the availability of and enrollment in therapeutic clinical trials. The same is true for supportive care studies which play a crucial role in improving quality of life.
Entities:
Keywords:
Adolescents; Cancer survivors; Clinical trials; Young adults
Authors: Helen M Parsons; Linda C Harlan; Nita L Seibel; Jennifer L Stevens; Theresa H M Keegan Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: Michael E Roth; Ann M O'Mara; Nita L Seibel; David S Dickens; Anne-Marie Langevin; Brad H Pollock; David R Freyer Journal: J Oncol Pract Date: 2016-03-29 Impact factor: 3.840
Authors: Pooja Rao; Joel E Segel; Lisa M McGregor; Eugene J Lengerich; Joseph J Drabick; Barbara Miller Journal: J Adolesc Young Adult Oncol Date: 2019-10-10 Impact factor: 2.223
Authors: David Victorson; Sofia F Garcia; Stacy Sanford; Mallory A Snyder; Sara Lampert; John M Salsman Journal: J Adolesc Young Adult Oncol Date: 2019-07-22 Impact factor: 2.223
Authors: Chelsea Anderson; Andrew B Smitherman; Clare Meernik; Teresa P Edwards; Allison M Deal; Nancy Cannizzaro; Christopher D Baggett; Chun Chao; Hazel B Nichols Journal: J Adolesc Young Adult Oncol Date: 2019-09-23 Impact factor: 2.223
Authors: Kee Kiat Yeo; Darcy E Burgers; Katelynn Brodigan; Karen Fasciano; A Lindsay Frazier; Katherine E Warren; David A Reardon Journal: Neurooncol Pract Date: 2021-02-18
Authors: Elizabeth J Siembida; Holli A Loomans-Kropp; Irene Tami-Maury; David R Freyer; Lillian Sung; Howland E Crosswell; Brad H Pollock; Michael E Roth Journal: JNCI Cancer Spectr Date: 2021-03-22
Authors: Pandora Patterson; Kimberley R Allison; Helen Bibby; Kate Thompson; Jeremy Lewin; Taia Briggs; Rick Walker; Michael Osborn; Meg Plaster; Allan Hayward; Roslyn Henney; Shannyn George; Dominic Keuskamp; Antoinette Anazodo Journal: Cancers (Basel) Date: 2021-05-28 Impact factor: 6.639